Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Brough

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Plos One|October 27, 2018
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
EMBO Molecular Medicine|January 6, 2010
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsAna M Mendes-Pereira, Sarah A Martin, Rachel Brough, et al.
Nature Genetics|March 3, 2025
The transcriptomic architecture of common cancers reflects synthetic lethal interactionsSyed Haider, Rachel Brough, Santiago Madera, et al.
Neuropsychological Rehabilitation|September 25, 2025
Supporting self-continuity during the hospital to community transition after acquired brain injury: A qualitative study of priorities, expectations and experiences of rehabilitationRachel Brough, Christy Hogan, Jessie Mitchell, et al.
Plos One|May 2, 2013
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicityStephen J Pettitt, Farah L Rehman, Ilirjana Bajrami, et al.
Stem Cells (Dayton, Ohio)|June 8, 2012
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancersAnna L Stratford, Kristen Reipas, Kaiji Hu, et al.
Communications Biology|November 9, 2021
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiencyIlirjana Bajrami, Callum Walker, Dragomir B Krastev, et al.
Oncogene|June 29, 2022
Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress toleranceDalia Tarantino, Callum Walker, Daniel Weekes, et al.
Molecular Oncology|October 22, 2023
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7Joseph S Baxter, Rachel Brough, Dragomir B Krastev, et al.
Cancer Research|November 19, 2013
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivityIlirjana Bajrami, Jessica R Frankum, Asha Konde, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Plos One|October 27, 2018
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
EMBO Molecular Medicine|January 6, 2010
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsAna M Mendes-Pereira, Sarah A Martin, Rachel Brough, et al.
Nature Genetics|March 3, 2025
The transcriptomic architecture of common cancers reflects synthetic lethal interactionsSyed Haider, Rachel Brough, Santiago Madera, et al.
Neuropsychological Rehabilitation|September 25, 2025
Supporting self-continuity during the hospital to community transition after acquired brain injury: A qualitative study of priorities, expectations and experiences of rehabilitationRachel Brough, Christy Hogan, Jessie Mitchell, et al.
Plos One|May 2, 2013
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicityStephen J Pettitt, Farah L Rehman, Ilirjana Bajrami, et al.
Stem Cells (Dayton, Ohio)|June 8, 2012
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancersAnna L Stratford, Kristen Reipas, Kaiji Hu, et al.
Communications Biology|November 9, 2021
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiencyIlirjana Bajrami, Callum Walker, Dragomir B Krastev, et al.
Oncogene|June 29, 2022
Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress toleranceDalia Tarantino, Callum Walker, Daniel Weekes, et al.
Molecular Oncology|October 22, 2023
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7Joseph S Baxter, Rachel Brough, Dragomir B Krastev, et al.
Cancer Research|November 19, 2013
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivityIlirjana Bajrami, Jessica R Frankum, Asha Konde, et al.
Pageof 7